Nitkowski hoping stem cells lead to comeback
By Dr. Matthew Watson
Left-hander C.J. Nitkowski appeared in 336 games, mostly in a relief role, over parts of 10 seasons. (AP)
The last known whereabouts of C.J. Nitkowski, in regard to his Major League career, was Washington, some seven years ago. It's entirely possible -- maybe even probable -- that this career is 100 percent over and out.
Yet there was Nitkowski on a field in the Dominican Republic last month, working in setup situations for Gigantes del Cibao in the middle of the Dominican Winter League's round-robin playoffs. Hoping, perhaps against hope, that some scout would take note of his new sidearm delivery and effectiveness against lefties and upper-80s gun readings and determine that he's worth another look. Hoping, basically, for one more chance -- a chance, he believes, that would have been completely out of the question if not for the blood-and-stem-cell treatments he received last summer. "From a medical standpoint," Nitkowski says, "[the treatments have] been a success. I'm healthy." But the route he took to get to this point is, in many ways, misunderstood. Nitkowski received treatment identical to the one that picked Bartolo Colon's ailing arm and career off the scrap heap and made him a prominent member of the Yankees rotation last season. It's a treatment that, in Colon's case, caused a bit of an uproar in the headlines last summer, as such labels as "disputed" and "controversial" were used to describe it. In reality, though, the use of one's own stem cells to promote healing in an injured area is far from a new development. In fact, the microfracture procedure that is becoming more and more common in the treatment of knee injuries (it was performed on Victor Martinez last month) is, at its core, a stem-cell procedure. In microfracture, tiny holes are drilled in the bone to allow marrow to drip out and repair damaged tissue -- the mesenchymal stem cells inside the marrow provide the repairing power. In the cases of Nitkowski and Colon, the mesenchymal stem cells were extracted from bone marrow and from body fat and then injected into a blood-poor area -- Nitkowski's left shoulder and Colon's right shoulder and elbow -- to promote healing. Now, is this really a reliable way to treat an ailing athlete? That's a subject of scrutiny. Embryonic stem cells are the cause of controversy all their own, given the ethical and political debates over their use and concern by some members of the medical community that they have the potential to become cancerous tumors. With mesenchymal stem cells, on the other hand, the debate is not over morals or safety but, rather, efficacy. "There's very little evidence that bone marrow stem cells taken from one site and injected into another will do anything," Theodore Friedmann, a geneticist at the University of California at San Diego who heads the World Anti-Doping Agency's (WADA) gene doping panel, told ESPN The Magazine recently. "The most likely outcome is that if you put stem cells in places that are unfamiliar to them, like a knee or shoulder, most of them will just die." WADA initially banned all blood-spinning therapies before reversing its position in 2011 after studies failed to demonstrate that they enhance performance the way steroids do. So WADA currently has no position on the use of stem-cell treatments. In the face of skepticism, you have the case of Colon, who in the spring of 2010 was unsigned, unable to get any of his old velocity on his fastball and seemingly at the end of a once-dazzling career. Dr. James Purita, founder of the Institute of Regenerative and Molecular Orthopedics in Boca Raton, Fla., traveled to the Dominican Republic to perform platelet-rich plasma (PRP) and stem-cell treatments to help repair ligament damage in Colon's elbow and aid a torn rotator cuff. "There was a stigma that it was illegal, because we did it in the Dominican," Purita said. "But it was just because he lived there." And there was another stigma. Because Colon not only returned to the Majors but thrived in the first half of the 2011 season, some wondered if the procedure could be labeled a performance-enhancer. When Colon's story became public, Purita was questioned by Major League Baseball officials to ensure that he did not use human growth hormone in the procedure. Purita has admitted using HGH when treating non-athletes but said he knows better than to do so in these cases. MLB did a complete investigation, and no further action was taken. "We're not reinventing the wheel here," Purita said. "We've done a number of these procedures on people from all the major sports, with the exception of hockey. We've done some of the top players. But we keep it very discreet." The reason for the discretion, beyond the obvious HIPAA standards, is that some teams are leery of or reluctant to trust these stem-cell treatments. Purita said that he performed the procedure this winter on a Major League free agent who expressed an explicit desire that word not get out, because he didn't want it to affect his contract negotiations. However, the case of Colon, who signed a one-year, $2 million contract with the A's this winter, makes one wonder if biologic stem cells could be the next medical revolution, following arthroscopy and the ulnar collateral ligament replacement known as Tommy John surgery. Nitkowski, for one, hopes to find out. A member of eight Major League teams over parts of 10 seasons from 1995-2005, the left-handed Nitkowski appeared in 336 games, mostly in a relief role. In 2006 he began a five-year stint pitching for various teams in Asia -- first in the Japanese Pacific League, then in the Korean Baseball Organization. A year ago, hoping for another shot in the bigs, he began working on a sidearm delivery, only to injure his shoulder. It was around that time that Nitkowski heard about Colon. Intrigued, he made a call to Purita's office, and, within weeks he was in Boca Raton to undergo the procedure himself. Purita first drew fat from Nitkowski's waist, then drew bone marrow from the left side of Nitkowski's lower back. The liquids were spun in a centrifuge at 2,000 rotations per minute for about 15 minutes, isolating the platelets. They were then inserted into syringes and placed under an LED light for about 20 minutes -- a process that supposedly "kick starts" the cells inside. Once this process was complete, Purita injected the platelet-rich plasma and stem cells into Nitkowski's labrum and rotator cuff. This is an important distinction. Under U.S. Food and Drug Administration guidelines, mesenchymal stem cells must be "minimally manipulated," meaning they can't be harvested in a lab for days or weeks or transported elsewhere. "Everything," Purita said, "has to be used the same day, on the same patient, and everything has to be done at the point of care." In Nitkowski's case, the whole process took about four hours. Much to his amazement, he had full range of motion within 24 hours. "The rehab starts right away," he said. "You have to commit to it, like any injury. I never thought I had the mindset to do the tedious rehab work. But if you want it bad enough, you'll do it." Nitkowski's stem-cell treatment was performed in July of last year. And per the usual protocol in Purita's treatment plan, Nitkowski had a second PRP treatment four weeks later. By November he was throwing off a mound, and he was pleased with how his arm felt and how his sidearm-delivered stuff worked in the Dominican Republic last month. "I was sitting at 86, 87 [mph] and hitting 88-89," he said. "That's more than enough [velocity] from that arm angle." Though he hasn't pitched in the bigs in seven years, Nitkowski believes he could help a team, and he's hoping someone will give him a tryout in Spring Training. "I at least want to get in front of people and be told no," he said. "I can live with that. I would love the opportunity. This is either going to happen fast, or it's not going to happen at all." Nitkowski's about to turn 39. But he's left-handed, and he's healthy. And he firmly believes the latter would not have been possible without the treatment he received. "My arm feels really good," he said. "Every pitcher has little tears. It just comes with the territory. But this seems like it could be a good maintenance plan." There are skeptics, and there are critics. Nitkowski knows how some people feel when they hear about stem-cell treatments or about Alex Rodriguez flying to Germany for blood-spinning therapy to address his chronic knee and shoulder problems. They wonder if that precious line between therapy and enhancement is being straddled too closely. Having experienced it for himself, Nitkowski is a believer in the safety, the purity and the benefits of the treatment he had performed on his arm. And he thinks many other athletes will follow. "This," he said, "is going to be mainstream sooner rather than later."
Anthony Castrovince is a reporter for MLB.com. Read his columns and his blog, CastroTurf, and follow him on Twitter at @Castrovince. This story was not subject to the approval of Major League Baseball or its clubs.
See the original post here:
Nitkowski hoping stem cells lead to comeback
- Getting a Stem Cell or Bone Marrow Transplant - October 21st, 2024
- Acquisition of durable insulin-producing cells from human adipose tissue-derived mesenchymal stem cells as a foundation for cell- based therapy of... - October 21st, 2024
- 1.5 Lakh Indians Register To Save Lives: Join the Mission To Fight Blood Cancer - The Better India - October 21st, 2024
- How Stem Cell and Bone Marrow Transplants Are Used to Treat Cancer - October 13th, 2024
- Stem Cell (Bone Marrow) Transplants - MD Anderson Cancer Center - October 13th, 2024
- Donating Bone Marrow and Stem Cells: The Process and What To Expect - October 13th, 2024
- What to expect as a stem cell or bone marrow donor - October 13th, 2024
- Structural organization of the bone marrow and its role in ... - October 13th, 2024
- Stem cell donor from down the road saved my life after global search - BBC.com - September 23rd, 2024
- Awaiting the call: family hopes to find blood stem cell donor - Claremont Courier - September 23rd, 2024
- Michigan woman one of first in world to successfully receive bone marrow from deceased donor - WDIV ClickOnDetroit - September 23rd, 2024
- Next-generation stem cell transplant: Revolutionizing a lifesaving cancer therapy - The Business Journals - September 23rd, 2024
- Sophie's life was saved by a stranger. Some in her position have an 'unfair' disadvantage - SBS News - September 23rd, 2024
- What Are Leukemia and Lymphoma and How Are They Treated? - LVHN News - September 23rd, 2024
- Giralt on MDS Transplant Timing and Candidacy - Targeted Oncology - September 14th, 2024
- Aging is associated with functional and molecular changes in distinct hematopoietic stem cell subsets - Nature.com - September 14th, 2024
- A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and... - September 14th, 2024
- ISU researcher blown away by blood cell replication discovery - Radio Iowa - September 14th, 2024
- Pausing biological clock could give boost to lab-produced blood stem cells - Phys.org - September 14th, 2024
- 9-year-old gets successful bone marrow transplant - The Times of India - September 14th, 2024
- Dr. Crandall: Stem Cell Treatment Heals the Heart - Newsmax - September 3rd, 2024
- Orion Corporation: Managers’ transactions – Hao Pan - August 19th, 2024
- BioCorRx Reports Business Update for the Second Quarter of 2024 - August 19th, 2024
- Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates... - August 19th, 2024
- Aligos Therapeutics Announces Reverse Stock Split - August 19th, 2024
- Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference - August 19th, 2024
- Protect Pharmaceutical Corp. (PRTT) Announces New CEO and New Director; Moves to Finalize the Karinca Logistics Merger - August 19th, 2024
- OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - August 19th, 2024
- CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern,... - August 19th, 2024
- NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process - August 19th, 2024
- Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination - August 19th, 2024
- Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns - August 19th, 2024
- Codexis Publishes FY2023 Sustainability Disclosures - August 19th, 2024
- MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns - August 19th, 2024
- First Successful Paediatric Allogeneic Bone Marrow Transplant In Bengaluru; Know All About The Procedure - Onlymyhealth - August 4th, 2024
- Is Stem Cell Transplant Often The Only Treatment Option For Blood Cancer Patients? Why So? - News18 - June 2nd, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 10th, 2024
- Bone Marrow Transplantation | Johns Hopkins Medicine - December 20th, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 26th, 2023
- ADSCC Bone Marrow Transplant and Cellular Therapy Congress 2023 to take place in Abu Dhabi - ZAWYA - November 18th, 2023
- Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of... - May 16th, 2023
- Family of 7-month-old in need of bone marrow transplant hosting donor registration event - CBS Pittsburgh - May 8th, 2023
- Anika Continues to Expand Addressable Market for Tactoset Injectable Bone Substitute with Additional 510(k) Clearance from FDA - Marketscreener.com - April 5th, 2023
- MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 -... - April 5th, 2023
- VOR BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - Marketscreener.com - March 25th, 2023
- BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100 - Marketscreener.com - March 17th, 2023
- BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected... - March 17th, 2023
- JASPER THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - March 9th, 2023
- For a range of unmet medical needs, India offers a fantastic opportunity to push cell and gene therapies: B .. - ETHealthWorld - March 9th, 2023
- NGM BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.com - March 1st, 2023
- Bone health: Tips to keep your bones healthy - Mayo Clinic - January 27th, 2023
- Bone marrow drive held for military wife with cancer - January 27th, 2023
- Bone cancer - Symptoms and causes - Mayo Clinic - January 27th, 2023
- Bone | Definition, Anatomy, & Composition | Britannica - January 19th, 2023
- Bone Definition & Meaning - Merriam-Webster - January 19th, 2023
- What Is Bone? | NIH Osteoporosis and Related Bone Diseases National ... - January 19th, 2023
- Anatomy of the Bone | Johns Hopkins Medicine - January 19th, 2023
- Bone Health: Is Eating Meat Healthy For Your Bones? - January 19th, 2023
- Bone Keeper | Deepwoken Wiki | Fandom - January 19th, 2023
- With blood and plasma donations in short supply, uniting communities to give the gift of life - Toronto Star - January 3rd, 2023
- Side Effects of a Bone Marrow Transplant (Stem Cell Transplant) - December 25th, 2022
- 28-year-old cancer patient at Nebraska Medicine advocates for diversity in bone marrow registry - KMTV 3 News Now Omaha - December 17th, 2022
- Stem Cell Technologies and Applications Market Report 2022-2032 - Yahoo Finance - December 9th, 2022
- Fred Hutch at ASH: Global insights on AML outcomes, COVID-19 and cancer, CD19 CAR T-cell therapy updates, latest on precision oncology and more -... - December 9th, 2022
- Types of Stem Cell and Bone Marrow Transplants - American Cancer Society - December 1st, 2022
- Getting a Stem Cell or Bone Marrow Transplant - American Cancer Society - December 1st, 2022
- Woman, 41, With Bubbles In Her Urine Dismissed By Doctors. Turns Out To Have The Blood Cancer Multiple Myeloma. - SurvivorNet - December 1st, 2022
- Stem cell and bone marrow transplants - Cancer Research UK - November 22nd, 2022
- Donating Bone Marrow Experience | Be The Match - November 22nd, 2022
- Learn How to Donate Bone Marrow | Be The Match - October 29th, 2022
- Stem Cell Transplantation Program - DanaFarber Cancer Institute - October 29th, 2022
- A CRISPR Alternative for Correcting Mutations That Sensitize Cells to DNA Damage - The Scientist - October 13th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 13th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Management, Personalized Medicine, and Genome... - October 13th, 2022
- Gene therapy approvals now at four with treatments for inherited anemia and degenerative brain condition but costs are stratospheric. Why? - Genetic... - October 13th, 2022
- Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene... - October 13th, 2022
- Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at... - October 13th, 2022
- Bone Marrow: What it is & Why it is Important - Cleveland Clinic - October 5th, 2022
- A protocol for isolation and culture of mesenchymal stem cells from ... - October 5th, 2022
- Are immunotherapy and chemotherapy the same thing? How cancer treatments work - Nebraska Medicine - October 5th, 2022